Background A substantial number of patients with rheumatoid arthritis have an inadequate
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …

Background Effective new therapies are needed for rheumatoid arthritis. Current therapies
target the products of activated macrophages; however, T cells also have an important role in …

Background: The selective co-stimulation modulator abatacept demonstrated efficacy for
treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of …

Objective To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA‐4Ig),
a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has …

Objective T cells are involved in the pathogenesis of rheumatoid arthritis (RA). In animal
models of autoimmune diseases, blockade of costimulatory molecules on antigen‐presenting …

Objectives: To assess the efficacy and safety of abatacept in methotrexate-naive patients
with early rheumatoid arthritis (RA) and poor prognostic factors. Methods: In this double-blind, …

… Becker holds a patent for abatacept, which is used in the clinical treatment of autoimmune
… Becker holds a patent for abatacept, which is used in the clinical treatment of autoimmune …

Objective: To investigate the efficacy and safety of abatacept in combination with etanercept
in patients with active rheumatoid arthritis during a 1-year, randomised, placebo-controlled, …

Background Several agents provide treatment for established rheumatoid arthritis (RA), but
a crucial therapeutic goal is to delay/prevent progression of undifferentiated arthritis (UA) or …

Objective To evaluate the efficacy, radiographic changes, and safety of abatacept and
methotrexate therapy through 2 years in a long‐term extension of a previously published 1‐year …